C3orf20

Across TCGA pan-cancer cohorts, C3orf20 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated C3orf20 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C3orf20 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C3orf20 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LUAD, UCEC, and KICH are the cancer types where C3orf20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.045	0.717	<.001	18	view →
UCEC	DFS	Median	All	0.821	0.631	.019	16	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
ACC	DFS	Median	IV	0.010	0.383	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
SKCM	DFS	Median	III,IV	0.188	0.652	.045	3	view →
STAD	DFS	Median	All	1.000	0.336	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

C3orf20–LUAD (DFS)

Open the LUAD breakdown →